INDGN · NSE
Indegene Limited
₹600.1
+1.41% (+₹8.35)
Prev. close
₹591.75
Volume
4,69,267
Delivery %
58.9%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Indegene Limited
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, North America, and internationally. It operates through Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other segments. The company provides AI-embedded commercialization services for biopharmaceutical, emerging biotech, and medical devices companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms, as well as provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Further, it engages in the professional, and scientific and technical activities. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
Details
Sector
Healthcare
Industry
Health Information Services
CEO
Mr. Manish Gupta
Headquarters
Bengaluru
Employees
4,687
Website
indegene.comExchange
View on NSE ↗Key stats
Market cap
₹14,249.81 Cr
P/E ratio (TTM)
35.6
Dividend yield
0.39%
EPS (TTM)
₹16.62
Beta (1Y · daily vs NIFTY 50)
0.80
Shares float
10.22 Cr
EPS · quarter ended Jun 2026
₹4.81
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹2,306.10 Cr | ₹2,589.60 Cr | ₹2,839.30 Cr | ₹3,510.50 Cr | |
| EBITDA | — | — | ₹454.10 Cr | ₹584.10 Cr | ₹641.50 Cr | ₹670.70 Cr |
| ₹149.00 Cr | ₹165.00 Cr | ₹266.10 Cr | ₹336.70 Cr | ₹406.70 Cr | ₹401.10 Cr | |
| Diluted EPS | — | — | ₹11.12 | ₹14.09 | ₹17.02 | ₹16.62 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹596.00 Cr | ₹1,353.00 Cr | ₹2,204.00 Cr | ₹2,546.00 Cr | ₹3,326.00 Cr | ₹4,620.00 Cr | |
| — | — | ₹502.58 Cr | ₹489.60 Cr | ₹101.60 Cr | ₹144.40 Cr | |
| Stockholders' equity | ₹324.31 Cr | ₹764.35 Cr | ₹1,064.00 Cr | ₹1,429.00 Cr | ₹2,616.00 Cr | ₹3,139.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹172.00 Cr | ₹297.00 Cr | ₹130.00 Cr | ₹508.00 Cr | ₹442.00 Cr | ₹651.00 Cr | |
| Investing cash flow | — | — | ₹-893.30 Cr | ₹-327.20 Cr | ₹-682.70 Cr | ₹-512.40 Cr |
| ₹-132.00 Cr | ₹233.00 Cr | ₹333.00 Cr | ₹-66.00 Cr | ₹288.00 Cr | ₹-83.00 Cr | |
| Capital expenditure | ₹-21.00 Cr | ₹-25.00 Cr | ₹-19.00 Cr | ₹-11.00 Cr | ₹-30.00 Cr | ₹-44.00 Cr |
| End cash position | — | — | ₹73.60 Cr | ₹188.60 Cr | ₹241.00 Cr | ₹300.80 Cr |
Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | May 24 | Jun 24–Jun 26(9Q) |
|---|---|---|
| Promoter | 0.00% | 0.00% |
| Public | 99.84% | 100.00% |
| Employee trusts | 0.16% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Indegene Limited | ₹13,803.11 Cr | ₹591.75 | 34.5 | 4.40 | 12.8% | 0.05 | +23.6% | +1.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 10
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
20 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Indegene Q2 FY27: Date and Expectations
Indegene's Q2 FY27 results date is unconfirmed as of September 10, 2026, with an outer deadline for publication set for November 14, 2026. The company's stock traded at Rs 577.80, up 0.50%, on September 10, 2026. Investors will compare the upcoming results against Q2 FY26 figures of Rs 804 crore revenue and Rs 102 crore profit.
Indegene Limited: German Subsidiaries Merge
Indegene Limited announced the merger of its German subsidiaries, Indegene Healthcare Germany GmbH and Trilogy Writing & Consulting GmbH, effective September 9, 2026. The surviving entity, Trilogy, will now operate as Indegene Healthcare Germany GmbH. The company stated this internal reorganization has no material impact on its business operations or financial position.